Literature DB >> 11232198

Iron-induced liver injury.

H L Bonkovsky1, R W Lambrecht.   

Abstract

Iron, either in the form of heme or non-heme compounds, is essential to life, but it can also pose serious health risks. The liver is a principal target for iron toxicity because it is chiefly responsible for taking up and storing excessive amounts of iron. The major hepatic toxicities of iron overload include damage to multiple cell types (hepatocytes, Kupffer cells, hepatic stellate cells) and to multiple subcellular organelles (mitochondria, lysosomes, and smooth endoplasmic reticulum). Heavy iron overload, as occurs in primary (hereditary) or secondary forms of hemochromatosis, may cause cirrhosis, liver failure, and hepatocellular carcinoma. In addition, iron has been shown to be a contributory factor in the development or progression of alcoholic liver disease, nonalcoholic liver steatohepatitis, chronic viral hepatitis, prophyria cutanea tarda, and, perhaps, in alpha 1-antitrypsin deficiency and end-stage liver disease, regardless of cause.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11232198     DOI: 10.1016/s1089-3261(05)70116-1

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  19 in total

1.  The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues.

Authors:  Raymond J Bergeron; Neelam Bharti; Jan Wiegand; James S McManis; Shailendra Singh; Khalil A Abboud
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

2.  The design, synthesis, and evaluation of organ-specific iron chelators.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; Neelam Bharti
Journal:  J Med Chem       Date:  2006-11-30       Impact factor: 7.446

Review 3.  Iron toxicity and chelation therapy.

Authors:  Robert S Britton; Katherine L Leicester; Bruce R Bacon
Journal:  Int J Hematol       Date:  2002-10       Impact factor: 2.490

4.  (S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; John R T Vinson; Hua Yao; Neelam Bharti; James R Rocca
Journal:  J Med Chem       Date:  2006-05-04       Impact factor: 7.446

Review 5.  Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review.

Authors:  Tyler J Severson; Siddesh Besur; Herbert L Bonkovsky
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

6.  Iron increases HMOX1 and decreases hepatitis C viral expression in HCV-expressing cells.

Authors:  Wei-Hong Hou; Lisa Rossi; Ying Shan; Jian-Yu Zheng; Richard-W Lambrecht; Herbert-L Bonkovsky
Journal:  World J Gastroenterol       Date:  2009-09-28       Impact factor: 5.742

7.  Desferrithiocin analogues and nephrotoxicity.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; Neelam Bharti; Shailendra Singh
Journal:  J Med Chem       Date:  2008-09-13       Impact factor: 7.446

8.  Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; Neelam Bharti; Shailendra Singh
Journal:  J Med Chem       Date:  2008-06-06       Impact factor: 7.446

9.  Impact of the 3,6,9-trioxadecyloxy group on desazadesferrithiocin analogue iron clearance and organ distribution.

Authors:  Raymond J Bergeron; Jan Wiegand; Neelam Bharti; Shailendra Singh; James R Rocca
Journal:  J Med Chem       Date:  2007-06-12       Impact factor: 7.446

10.  Metabolically programmed iron chelators.

Authors:  Raymond J Bergeron; Neelam Bharti; James S McManis; Jan Wiegand
Journal:  Bioorg Med Chem       Date:  2015-06-29       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.